• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of angiogenic therapy for ischemic heart disease using anaerobic vector

Research Project

Project/Area Number 15K08023
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Drug development chemistry
Research InstitutionShinshu University

Principal Investigator

WADA YUKO  信州大学, 学術研究院医学系(医学部附属病院), 講師 (30419410)

Co-Investigator(Kenkyū-buntansha) 瀬戸 達一郎  信州大学, 学術研究院医学系, 准教授 (70362118)
Research Collaborator TANAKA Yuki  信州大学, 医学部, 技能補佐員
Project Period (FY) 2015-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords血管新生療法
Outline of Final Research Achievements

In this study we showed that B.Longum (BL), an anaerobic bacterium, accumulates specifically in the myocardial infarction site by intravenous administration, and are promptly removed from the non-ischemic site. This finding indicates that BL may be useful vector for ischemic heart disease.
We developed the new therapeutic angiogenesis drug for ischemic heart disease, FGF-BL incorporating bFGF gene into this vector, and performed a therapeutic experiment on guinea pig myocardial infarction model using FGF-BL. We confirmed that FGF-BL was specifically delivered to myocardial infarction site, but this agent did not show improvement effect for LV function.

Report

(4 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • 2015 Research-status Report

URL: 

Published: 2015-04-16   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi